Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus Paracasei OFS 0291 (LP-0291) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 5/March/2019, 6.12 pm

Molecular therapy for autoimmune diabetes (TIDM): Extendin-4(brand name: Byetta, Bydureon, Exenatide), a GLP-1 receptor agonist, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 5/March/2019, 5.59 pm
March 5, 2019
Probiotic-based therapy for diabetes: Probiotic bifidobacterium CECT 7765  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 5/March/2019, 6.35 pm
March 5, 2019
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests a probiotic-based therapy for lowering cholesterol and triglyceride levels, and to treat Non-alcoholic fatty liver disease (NAFLD).

Probiotic Lactobacillus Paracasei OFS 0291 (LP-0291), by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, probiotic Lactobacillus Paracasei OFS 0291 (LP-0291), either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how Lactobacillus Paracasei OFS 0291 (LP-0291) decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

 Figure 2.  Lactobacillus Paracasei OFS 0291 (LP-0291) functions as a cholesterol-lowering agent. LP-0291 lowers cholesterol and triglyceride levels and attenuates NAFLD, through down-regulation of HMGCR

[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Lactobacillus Paracasei OFS 0291 (LP-0291) decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus Paracasei OFS 0291 (LP-0291) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 5/March/2019, 6.12 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Comments are closed.